17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Corcept Therapeutics Inc (CORT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 5,758,528 | $200,396,774 | -6% | 0.31% |
| 2. | Bridgewater Associates Ray Dalio | 279,000 | $9,709,200 | -9% | 0.04% |
| 3. | Hudson Bay Capital Management Sander Gerber | 185,800 | $6,465,840 | 0.02% | |
| 4. | 185,800 | $6,465,840 | 0.02% | ||
| 5. | Walleye Capital Will England | 180,401 | $6,277,955 | +56100% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.53 | 100,000 | $2,153,000.00 | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | $1,076,500.00 | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | $1,539.52 | 3,208,303 | 2020-12-01 | Filing | |
| $22.80 | 1,109 | $25,285.20 | 3,208,235 | 2020-11-30 | Filing | |
| $22.81 | 361 | $8,232.79 | 3,207,126 | 2020-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.87 | 20,000 | $817,334.00 | 1,235 | 2026-02-03 | Filing | |
| $35.18 | 20,000 | $703,656.00 | 1,235 | 2026-01-06 | Filing | |
| $80.88 | 640 | $51,760.00 | 1,235 | 2025-12-02 | Filing | |
| $80.05 | 19,360 | $1,549,766.06 | 1,875 | 2025-12-02 | Filing | |
| $79.52 | 20,000 | $1,590,490.00 | 7,904 | 2025-12-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,062,212 | $419,764,959 | 0.01% | |
| 2. | 9,494,822 | $330,419,806 | 0% | |
| 3. | 3,879,141 | $134,994,107 | 2.47% | |
| 4. | 2,986,056 | $103,914,749 | 0% | |
| 5. | 2,668,918 | $92,891,503 | 0.01% |
News See All
Corcept Therapeutics (CORT) Climbs 26.6% on Stellar Clinical Trial Result
Corcept Therapeutics saw its share prices jump by 26.6 percent week-on-week, as investors took heart from the strong clinical trial results of its drug candidate, relacorilant, in patients with platinum...
Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results
Corcept Therapeutics extended its winning streak to a third consecutive day on Thursday, jumping 13.74 percent to close at $41.30 apiece as investors cheered clinical results from its late-stage study...
Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts?
Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the most promising growth stocks according to analysts.
13 Most Promising Growth Stocks According to Analysts
In today's market, shaped by continuous innovation and evolving macro backdrops, investors are wondering: which stocks to invest in? While many believe in investing in low-risk stocks, a large proportion...
12 Stocks that Will Bounce Back According to Wall Street Analysts
On January 5, Reuters reported that many analysts believe global investors will actively look for opportunities in undervalued areas of the financial markets in 2026.
Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch
On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target.
15 Stocks That Could Mint Millionaires in 2026
For more than a century, investing in the stock market in the United States has represented one of the most accessible paths to generating substantial wealth for the amateur investor, with a long and ...
Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts. On November 25, H.C.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Hedge Fund Resource Center Billionaire Hedge Funds
